Le Lézard
Classified in: Health
Subjects: PDT, SVY, TRI, MIN

DolCas Biotech's Botanical Blend, Fortiquin, Supports Men's Sexual Health


LANDING, N.J., Oct. 13, 2020 /PRNewswire/ -- A synergistic five-ingredient botanical formula demonstrated significant benefits in the support of men's healthy sexual performance in recently published clinical research. These findings demonstrate the effectiveness of Fortiquin tm(OLNP-05) in supporting healthy sexual male performance, an issue that affects 20% to 30% of men globally.

In this double-blind, controlled study published July 14, 2020, in the Journal of Medicinal Food, the patent-pending, all-natural Fortiquin (OLNP-05) herbal fusion marketed by DolCas Biotech, Ltd., exhibited a 5.1-fold benefit over a placebo in safely supporting  healthy sexual endurance and stamina amongst healthy male subjects over an 8 week course.

Fortiquin (OLNP-05) is a standardized blend of extracts of mucuna seed, fenugreek seed, artichoke leaf, and ashwagandha root, alongside the amino acid L-arginine. It is formulated to nourish the nervous and hormonal systems and fortify the stress response as it supports healthy sexual endurance and control in men.

Fortiquin rides the wave of newly held interest in botanical synergism and the magnified benefits found in complementary formulated ingredients. "DolCas Biotech describes its concept of formulation as 'informed by the wisdom of traditional practices such as Ayurveda, Traditional Chinese Medicine', among other natural healing practices around the world ? which have always held in high-esteem multi-botanical versus single ingredient approaches," explains Shavon Jackson-Michel, N.D., Director of Medical & Scientific Affairs for DolCas.

"The individual herbs in Fortiquin exist as extracts ? not powders ? delivering an enriched profile of the phytochemicals most associated with the herbs' activity and organ affinity," adds Jackson-Michel. "The synergistic blend retains an exclusive fingerprint for standardization, protecting the inventiveness of the brand, while at the same time complying with highest quality standards for consistency and traceability."

Concerns of shortened sexual endurance in men can be life-long or acquired, with the acquired form of it being associated with psychological fluctuations that can evolve from stressful experiences and events. Reciprocally, low sexual endurance has been shown to effect mood, confidence, and a man's sense of well-being, with additional relational stress as a compounding consequence. Natural products are widely regarded for their anecdotal benefits for male sexual issues, but limited in their scope due to insufficient evidence, product inconsistency, and questionable safety.

Male consumers can be comforted by the comprehensive standardization of the formula, at 1.5% flavonoids and 20% saponins, and the protection of a patented trademark formulation that ensures consistency from batch to batch. The safety of Fortiquin (OLNP-05) in the clinical study was assessed by physical examination, vital signs, and monitoring for adverse events or changes to lab parameters. There was no statistically significant difference in the number of adverse events and no remarkable changes in laboratory parameters, including red and white blood cell assessment, liver and kidney function. All vital signs were unaltered throughout the study.

About DolCas Biotech, LLC.:

DolCas Biotech has a proven track record of success positioning curcumin products in the global nutraceuticals market, amassing nearly a decade of experience of successful commercialization within the branded curcumin space.

For more information, contact:

Company contact:

Press Contact:

DolCas Biotech, LLC

NutriPR

Dr. Shavon Jackson-Michel

Liat Simha

Director of Medical & Scientific Affairs

Tel: +972-9-9742893

Tel: 973-347-1958 ext. 217

E-mail: [email protected]

Email: [email protected]

Website: www.nutripr.com

Web: www.dolcas-biotech.com

Twitter: @LiatSimha

 

 

SOURCE DolCas Biotech


These press releases may also interest you

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...

at 17:49
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 17:33
The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the United States, announced the overwhelming success of its 2024 "Are You O-K+" campaign, which marked May 1 (5.1) as...

at 17:21
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and...

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...



News published on and distributed by: